MDT

99.36

+1.42%↑

146.53

+0.24%↑

VEEV

219.29

+0.75%↑

HQY

88.47

+3.78%↑

NEOG

9.51

+3.71%↑

MDT

99.36

+1.42%↑

146.53

+0.24%↑

VEEV

219.29

+0.75%↑

HQY

88.47

+3.78%↑

NEOG

9.51

+3.71%↑

MDT

99.36

+1.42%↑

146.53

+0.24%↑

VEEV

219.29

+0.75%↑

HQY

88.47

+3.78%↑

NEOG

9.51

+3.71%↑

MDT

99.36

+1.42%↑

146.53

+0.24%↑

VEEV

219.29

+0.75%↑

HQY

88.47

+3.78%↑

NEOG

9.51

+3.71%↑

MDT

99.36

+1.42%↑

146.53

+0.24%↑

VEEV

219.29

+0.75%↑

HQY

88.47

+3.78%↑

NEOG

9.51

+3.71%↑

Kodu・Aktsiate loetelu・Celldex Therapeutics Inc

Celldex Therapeutics Inc

Avatud

SektorTervishoid

25.73 -2.17

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

25.15

Max

26.55

Põhinäitajad
By Trading Economics
Sissetulek	-10M -67M
Kasumimarginaal	-7,753.425
Töötajad	186
EBITDA	-9.8M -73M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+112.11% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	25. veebr 2026

Turustatistika
By TradingEconomics
Turukapital	200M 1.7B
Eelmine avamishind	27.9
Eelmine sulgemishind	25.73

Uudiste sentiment

By Acuity

50%

151 / 361 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

18.91 / 20.63 Toetus ja vastupanu

Celldex Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

14. jaan 2026, 22:41 UTC

Omandamised, ülevõtmised, äriostud

Canadian Natural Resources, Tourmaline File Deal Notice With Antitrust Regulator

15. jaan 2026, 00:00 UTC

Tulu

Welcome to Greenland, an Economy Reliant on Subsidies and Shrimp -- WSJ

14. jaan 2026, 23:47 UTC

Market Talk

Oil Slips After Trump Appears to Tilt Away From Military Action in Iran -- Market Talk

14. jaan 2026, 23:44 UTC

Market Talk

Nikkei May Decline After Hitting Record Highs; Election in Focus -- Market Talk

14. jaan 2026, 23:39 UTC

Market Talk

ANZ's New Bull Still Sees Valuation Gap to Peers -- Market Talk

14. jaan 2026, 23:32 UTC

Market Talk

Gold Declines on Likely Technical Correction, Possible Profit-Taking -- Market Talk

14. jaan 2026, 22:56 UTC

Omandamised, ülevõtmised, äriostud

Soho House Amends Rollover and Support Agreements With Broad Street Principal Investments and Others

14. jaan 2026, 22:53 UTC

Omandamised, ülevõtmised, äriostud

Soho House: Apollo Global Management and Goldman Sachs Asset Management Amend Debt Commitment

14. jaan 2026, 22:17 UTC

Market Talk

Global Equities Roundup: Market Talk

14. jaan 2026, 22:17 UTC

Market Talk

WiseTech's Revenue Growth Drivers Attract Scrutiny -- Market Talk

14. jaan 2026, 22:09 UTC

Tulu

CITIC Securities: Uptrend in China Capital Markets Supported Results >600030.SH

14. jaan 2026, 22:08 UTC

Tulu

CITIC Securities 2025 Oper Rev CNY74.83B Vs. CNY58.12B >600030.SH

14. jaan 2026, 22:08 UTC

Tulu

CITIC Securities 2025 Net CNY30.05B Vs. Net CNY21.57B >600030.SH

14. jaan 2026, 21:53 UTC

Omandamised, ülevõtmised, äriostud

WuXi XDC Expects 2025 Net to Increase Over 38% on Year

14. jaan 2026, 21:53 UTC

Omandamised, ülevõtmised, äriostud

WuXi XDC Expects 2025 Revenue to Increase More Than 45% on Year

14. jaan 2026, 21:52 UTC

Omandamised, ülevõtmised, äriostud

WuXi XDC Announces Positive Profit Alert for 2025

14. jaan 2026, 21:51 UTC

Omandamised, ülevõtmised, äriostud

Citigroup Acting as Financial Advisor to WuXi XDC

14. jaan 2026, 21:51 UTC

Omandamised, ülevõtmised, äriostud

WuXi XDC: Aims to Keep Listing Status of BioDlink

14. jaan 2026, 21:51 UTC

Omandamised, ülevõtmised, äriostud

WuXi XDC: Company to Finance BioDlink Shares Acquisition via Internal Resources

14. jaan 2026, 21:50 UTC

Market Talk

Tulu

Financial Services Roundup: Market Talk

14. jaan 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

14. jaan 2026, 21:49 UTC

Omandamised, ülevõtmised, äriostud

WuXi XDC: BioDlink Offer to Cost HK$2.79B

14. jaan 2026, 21:48 UTC

Omandamised, ülevõtmised, äriostud

WuXi XDC Offers to Pay HK$4.00 for Each BioDlink International Share

14. jaan 2026, 21:48 UTC

Omandamised, ülevõtmised, äriostud

WuXi XDC Makes Cash Offer for BioDlink International

14. jaan 2026, 21:13 UTC

Market Talk

Oil Retreats Late After Trump Comments on Iran -- Market Talk

14. jaan 2026, 20:30 UTC

Market Talk

Tulu

Danaher's Preliminary 4Q Seen as Promising -- Market Talk

14. jaan 2026, 20:13 UTC

Market Talk

U.S. Natural Gas Futures Sink Ahead of Storage Report -- Market Talk

14. jaan 2026, 20:08 UTC

Market Talk

Oil Futures Extend Rally on Iran Tensions -- Market Talk

14. jaan 2026, 19:33 UTC

Market Talk

Nutrien Seen as Winner in Tighter 2026 Potash Market, Higher Prices -- Market Talk

14. jaan 2026, 19:06 UTC

Market Talk

Tulu

Wells Fargo Says Customers, Economy Remain Resilient -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Celldex Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

112.11% tõus

12 kuu keskmine prognoos

Keskmine 55 USD 112.11%

Kõrge 90 USD

Madal 24 USD

Põhineb 10 Wall Streeti analüütiku instrumendi Celldex Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

10 ratings

Osta

Hoia

Müü

Põhineb 10 analüütiku instrumendi Celldex Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

18.91 / 20.63Toetus ja vastupanu

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

151 / 361 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.